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A cut-off serum creatinine value of 1.5 mg/dl for AKI – To be
or not to be
JOURNAL OF HEPATOLOGYTo the Editor:
Acute renal failure (ARF) is a common problem in patients with
decompensated cirrhosis and ascites [1]. Traditionally, the diag-
nosis of ARF is made using the conventional criteria of a 50%
increase in serum creatinine with the ﬁnal serum creatinine
reaching P1.5 mg/dl [2]. More recently, it has been recognized
in non-cirrhotic patients that smaller increases in serum creati-
nine also have a negative impact on survival [3]. This has led var-
ious learned societies to re-deﬁne ARF as acute kidney injury
(AKI), incorporating even small changes in serum creatinine either
in absolute or percentage terms in the diagnostic criteria [4–6].
The degree of AKI severity is also deﬁned by stages [4–6]. The
most commonly reported classiﬁcation used to diagnose AKI is
that of the Acute Kidney Injury Network (AKIN), which set forth
speciﬁc serum creatinine and urine output changes to deﬁne
stages of AKI, without setting a ﬁxed serum creatinine level in
its diagnostic criteria [5]. Comparison of results from various
studies in patients with cirrhosis has been difﬁcult, as these stud-
ies assessed cirrhotic patients of various disease severities, in dif-
ferent hospital settings, using differentmethodologies to calculate
the change in serum creatinine [7–9]. Emerging from these
studies are the ﬁndings that both the severity of AKI, as well as
the progression of AKI have a negative impact on patient survival.
In two recent articles by Fagundes et al. [10], and Piano et al. [11],
published in the Journal of Hepatology, which evaluated the impact
of AKI on short-term mortality in patients with decompensated
cirrhosis, admitted to the hospital for various reasons, similar
trends were reported. Both studies incorporated parts of the AKIN
criteria using the conventional criteria for the diagnosis of AKI.
Fagundes et al. found that patients with stage 1 AKI (increase in
serum creatinine by either 0.3 mg/dl or by 50% irrespective of
the ﬁnal serum creatinine) and peak serum creatinine of
61.5 mg/dl had a very good survival, similar to that of non-AKI
patients [10]. Piano et al. found that the conventional diagnostic
criteria, using a cut-off serum creatinine of 1.5 mg/dl was better
than the AKIN criteria in the prediction of survival. This is not
surprising, as the conventional diagnostic criteria tend to select
out patients with more severe kidney injury. Furthermore, a
serum creatinine of P1.5 mg/dl was able to predict progression
of AKI [11]. Based on these two studies, Fagundes et al. proposedJournal of Hepatology 20
Open access under CC BY-NC-ND license.instituting a new classiﬁcation of AKI in cirrhosis, separating cir-
rhotic patients with AKI into 3 subgroups: (i) stage 1 with a ﬁnal
serum creatinine of61.5 mg/dl, (ii) stage 1 with a ﬁnal serum cre-
atinine of >1.5 mg/dl, and (iii) combined stages 2 and 3. Piano et al.
suggested that future interventional trials should incorporate
certain aspects of the AKIN criteria, namely, small increment of
0.3 mg/dl in serum creatinine and staging, to allow assessment
of progression, while maintaining the conventional diagnostic
criteria, requiring a minimum serum creatinine ofP1.5 mg/dl.
Therefore, these two studies seem to suggest a serum creati-
nine cut-off value of 1.5 mg/dl is important in the management
of AKI and the prediction of patient outcome in cirrhosis. These
studies also imply that AKI episodes with a lower peak serum cre-
atinine may not be clinically important., and may not require
intervention However, as Thalheimer and Burroughs pointed
out, AKI with a peak serum creatinine of <1.5 mg/dl is not a
benign condition [12]. One has to emphasize that the above
two studies were designed speciﬁcally to evaluate the impact of
AKI on short-term survival in a very speciﬁc population of cir-
rhotic patients, namely hospitalized cirrhotic patients. They did
not set out to evaluate the impact of AKI on other events that
could be important in the natural history of cirrhosis, such as
recurrence of AKI, the development of future complications, or
future hospitalizations. In light of the marked variation in base-
line creatinine between cirrhotic patients, using a speciﬁc serum
creatinine cut-off value could potentially result in the late diag-
nosis of AKI, and delay interventions. In a totally different setting
of outpatient decompensated cirrhotics, Tsien et al. reported that
patients with AKI, deﬁned as a rise in serum creatinine by either
0.3 mg/dl within <48 h or an increase of 50% from a stable value
in the previous 6 months, and a mean peak serum creatinine
within the normal laboratory range had a worse prognosis com-
pared to those without AKI when followed for 12 months [13]. In
another cohort of hospitalized decompensated cirrhotic patients
with infection (n = 337) [14], a higher percentage of those who
developed AKI (n = 166) died within 30 days, despite receiving
the standard of care for their AKI plus prompt antibiotic treat-
ment. Re-analysis of the data showed that of the 166 patients
who developed AKI, there were 31 patients whose peak serum
creatinine was 61.5 mg/dl (group A), and 135 patients whose15 vol. 62 j 739–752 741
peak serum creatinine was >1.5 mg/dl (group B). 81% of group A
patients survived 30 days vs. 93% of control subjects, p = 0.038
(Fisher’s exact test) (Fig. 1). Interestingly, the 30 day survival of
group B (63%) was statistically similar to that of group A
(p = 0.09) despite group B having signiﬁcantly more organ fail-
ures (group A: median number of organ failure = 1, interquartile
range 0:1; group B: median number of organ failure = 1, inter-
quartile range 1:2) (p = 0.008, Mann-Whitney U test). Therefore,
in different clinical settings to those of Fagundes et al., and Piano
et al., using the conventional criteria of serum creatinine of
P1.5 mg/dl to diagnose AKI may lead to clinical decisions that
could be detrimental to these patients.
The diagnosis of AKI in cirrhosis is currently still a matter
under discussion. We have borrowed the AKIN criteria from
nephrologists [5], but do not really adhere strictly to the diag-
nostic criteria of AKIN for the diagnosis of AKI, as no study to
date has incorporated the urine output criteria of the AKIN def-
inition. This is reasonable because cirrhotic patients have issues
that are particular to themselves, such as lower urine output
even without AKI, due to avid sodium and water retention. Cir-
rhotic patients also have malnutrition, leading to lower muscle
mass, thereby artiﬁcially lowering the serum creatinine [15].
This is particularly problematic in female patients, whose
serum creatinine signiﬁcantly overestimates renal function; uti-
lization of a 1.5 mg/dl cut-off for diagnosing clinically signiﬁ-
cant AKI may discriminate against women [16]. Therefore,
academic societies are working together to try to identify the
best uniﬁed diagnostic criteria for AKI in cirrhosis. Although
Fagundes et al. and Piano et al. have provided robust results
for their particular sets of patients, their results may not be
generalizable and equitable to other patients with cirrhosis.
Therefore, to use results of selected individual studies to pro-
pose widespread changes in diagnostic criteria for AKI may
be premature. Rather, these studies should stimulate the per-
formance of prospective trials that will clarify the best timing
to initiate therapy for renal dysfunction that will prevent its
progression, thereby improving the survival of this fragile pop-
ulation of patients with decompensated cirrhosis.
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Fig. 1. Patient survival. Percentage of patients who survived more than 30 days
amongst cirrhotic patients with infection, and who did not develop acute kidney
injury (Group A), who developed acute kidney injury but the peak serum
creatinine remained 61.5 mg/dl (Group B), and who developed acute kidney
injury but the peak serum creatinine was >1.5 mg/dl (Group C).
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Reply to: ‘‘A cut-off serum creatinine value of 1.5 mg/dl for AKI – To
be or not to be’’
To the Editor
We really appreciate the interest ofWong and colleagues, from the
North American Consortium in the Study of End-Stage Liver
Disease (NACSELD) group, on our study published in the Journal
of Hepatology in late 2013 [1]. As a research group interested in
kidney dysfunction in cirrhosis, we share the concerns of our
American colleagues about improving the diagnosis and
management of kidney dysfunction in cirrhosis. Needless to say,
we agree on their comments about the need for improving the
interpretation of the relationship between glomerular ﬁltration
rate and serum creatinine values in women. This is particularly
important in the application of theMELD score for organ allocation
in liver transplantation. We would be willing to join efforts with
our American colleagues to further investigate this issue. That said,
we would like to highlight 4 important issues related to their
letter:
(1) The study of Fagundes et al. [1] was a prospective evaluation
of all patients requiring hospital admission for an acute
decompensation of cirrhosis, during a 26-monthperiod,with
the only exceptions of patientswith large hepatocellular car-
cinoma, previous solid organ transplantation, and those on
renal replacement therapy. Therefore, our study population
included ‘‘all comers’’ to a tertiary hospital. We do not know
whether our results apply to similar populations of patients
with cirrhosis in other tertiary hospitals or to different popu-
lations in other settings. The new classiﬁcation proposed
(categorizing AKI stage 1 in two subgroups-A and B- and
combining stages 2 and 3) was internally validated, but we
obviously stated in the manuscript that it would require
external validation in future studies before it could bewidely
applicable. Nonetheless, it is important to remark that in the
same issue of the Journal, in which our study was published,
Piano et al. reported amazingly similar results in a population
of ‘‘all comers’’ with decompensated cirrhosis, in a tertiary
hospital in Northern Italy [2].
(2) Wong et al. disapprove of our proposal for this modiﬁed AKI
classiﬁcation that uses the cut-off value of serum creatinine
of 1.5 mg/dl, to categorize patients with AKI stage 1. In our
opinion, as well as that of others, the use of a cut-off of
serum creatinine makes perfect pathophysiological sense
because it helps put into perspective the relative increase
in serum creatinine used in the AKIN classiﬁcation. In this
regard, it is clear that a 50% increase in serum creatinine
is markedly dependent on the baseline creatinine value.
In fact, a 50% increase does not have the same signiﬁcance
in a patient with a baseline serum creatinine level of
0.6 mg/dl, compared to that of a patient with a baseline
level of 1.2 mg/dl. In the ﬁrst case, the ﬁnal value is
0.9 mg/dl, which despite the 50% raise still represents a
relatively preserved glomerular ﬁltration rate. By contrast,
in the second case the ﬁnal value is 1.8 mg/dl, which
corresponds to a very low glomerular ﬁltration rate, indi-
cating the presence of signiﬁcant organ failure. If we trans-
late this example to the liver using serum bilirubin as
marker of liver function, it is clear that a 50% increase in
serum bilirubin does not represent the same degree of liver
failure when the ﬁnal value of bilirubin is 3 mg/dl or 12
mg/dl.
(3) Another argument used by Wong et al. to refute our
classiﬁcation based on a cut-off level of serum creatinine
of 1.5 mg/dl, is that it could result in late diagnosis of
AKI and delayed interventions. We disagree with this
interpretation of our ﬁndings. Nowhere in our study it
is stated that patients with AKI stage 1A should not be
treated for AKI. In fact, all patients diagnosed at AKI
stage 1A (serum creatinine <1.5 mg/dl) were investigated
to determine the cause of AKI and received immediate
treatment, whenever a cause of AKI was identiﬁed.
Moreover, with our approach, the majority of patients
(77%) were diagnosed at AKI stage 1, while only 12%
were diagnosed at stage 3, which clearly seems to indi-
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